Short Interest in ICU Medical, Inc. (NASDAQ:ICUI) Rises By 14.0%

ICU Medical, Inc. (NASDAQ:ICUI) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 838,100 shares, an increase of 14.0% from the December 15th total of 735,400 shares. Based on an average daily trading volume, of 217,900 shares, the short-interest ratio is currently 3.8 days. Currently, 3.7% of the company’s shares are short sold.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $163.87 on Monday. The firm has a market capitalization of $4.01 billion, a P/E ratio of -35.86 and a beta of 0.63. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical has a 52 week low of $86.80 and a 52 week high of $196.26. The firm’s 50 day moving average is $161.73 and its two-hundred day moving average is $159.45.

Insider Activity at ICU Medical

In other news, Director David C. Greenberg sold 972 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the transaction, the director now directly owns 5,037 shares in the company, valued at $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $171.84, for a total value of $2,062,080.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $17,973,261.12. This represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,737 shares of company stock worth $4,941,832. Company insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several hedge funds have recently made changes to their positions in the company. Allworth Financial LP lifted its stake in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 100 shares during the last quarter. Xponance Inc. increased its holdings in shares of ICU Medical by 6.0% in the 2nd quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after acquiring an additional 112 shares during the period. Equitable Trust Co. raised its position in ICU Medical by 2.2% in the 3rd quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier’s stock valued at $950,000 after purchasing an additional 112 shares during the last quarter. Hexagon Capital Partners LLC boosted its stake in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the period. Finally, Connable Office Inc. grew its position in ICU Medical by 6.4% during the 3rd quarter. Connable Office Inc. now owns 2,031 shares of the medical instruments supplier’s stock worth $370,000 after purchasing an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

ICUI has been the subject of several research reports. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Wednesday, December 11th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. KeyCorp increased their price target on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $199.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.